CVM
CEL-SCI Corporation | Healthcare
0%
Analisi Pre-Earnings (Antonio AI)
2025-12-18Sentiment
75.0/100
Salute
Weak
Verdict
Il titolo è spinto da catalizzatori potenti sul mercato saudita, creando un'opportunità speculativa pre-utili. 🔥 Attenzione però, l'azienda brucia cassa e si finanzia diluendo costantemente gli azionisti, una vera e propria macchina da offerte pubbliche. ⚠️
Catalysts
- Progressi verso la commercializzazione e partnership strategica in Arabia Saudita per il farmaco Multikine.
- Potenziale 'Breakthrough Medicine Designation' che potrebbe accelerare l'accesso al mercato e le vendite.
Rischi
- Diluizione continua e massiccia del capitale attraverso frequenti offerte pubbliche per sostenere il cash burn operativo.
Valutazione
| P/E (TTM) | -0.8474603671718967 |
| Forward P/E | -0.8474603671718967 |
| P/S | 5.990643864835183 |
| Market Cap | None |
Finanze & Debito
| Cash | None |
| Debt | None |
| Debt/Equity | 1.418364000261924 |
| Current Ratio | 0.46697054583579056 |
Redditività
| ROE | -2.5939401268058404 |
| Profit Margin | -4.269908852473776 |
| Operating Margin | -4.182084073690714 |
| Rev. Growth | 0.0 |
Ultime News (Context per AI)
-
CEL-SCI Reports Fiscal 2025 Results 2025-12-29 09:00:00
businesswire.com
-
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025 2025-10-20 09:00:00
newsfilecorp.com
-
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference 2025-10-10 08:00:00
newsfilecorp.com
-
Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension 2025-08-30 07:15:00
globenewswire.com
-
CEL-SCI Announces Closing of $10 Million Public Offering 2025-08-29 12:52:00
businesswire.com
-
CEL-SCI Announces Pricing of $10 Million Public Offering 2025-08-27 22:35:00
businesswire.com
-
CEL-SCI Announces Proposed Public Offering 2025-08-27 17:25:00
businesswire.com
-
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results 2025-08-14 10:45:00
businesswire.com
-
businesswire.com
-
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules 2025-07-14 16:05:00
businesswire.com
-
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer 2025-07-11 09:15:00
businesswire.com
-
businesswire.com
-
CEL-SCI Announces Closing of Public Offering 2025-05-23 16:05:00
businesswire.com
-
CEL-SCI Announces Pricing of Public Offering 2025-05-21 20:14:00
businesswire.com
-
CEL-SCI Announces Proposed Public Offering 2025-05-21 16:05:00
businesswire.com